---
document_datetime: 2023-09-21 17:59:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/neospect-epar-procedural-steps-taken-authorisation_en.pdf
document_name: neospect-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4563026
conversion_datetime: 2025-12-22 20:46:06.820063
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Nycomed  Imaging  AS  submitted  on  26  October  1998  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for NeoSpect,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  27  July  2000,  this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

•

- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 29 November 2000.

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr Mary Teeling Co-Rapporteur: Dr Jens Ersbøll Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 20 November 1998 · The Rapporteur's first assessment report was circulated to all CPMP Members on 29 January 1999. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 29 January 1999 · During  the  meeting  on  23  -  25  March  1999,  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the Applicant on 25 March 1999 (Annex 3). · The  Applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  22 September 1999 · The summary report of the inspection carried out at the manufacturing site on 27 January 2000 was issued on 3 February 2000 (Annex 4). · The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 23 November 1999 (Annex 5). · During the CPMP meeting on 14 - 16 December 1999, outstanding issues were addressed by the applicant during a hearing before the CPMP.  A 6 month clock stop was agreed to allow the Applicant to finalise a clinical study. · The  CPMP  Consolidated  Assessment  Report  and  List  of  Outstanding  Issues  (dated  16 December 1999) was sent to the Applicant on 17 December 1999. · The Applicant submitted the responses to the CPMP Consolidated Assessment Report and List of Outstanding Issues on 19 June 2000. During the meeting on 25 - 27 July 2000 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  (majority)  for granting a Marketing Authorisation to NeoSpect on 27 July 2000.